DEVELOPMENT OF FROVATRIPTAN SUCCINATE MICROEMULSION FOR NASAL DELIVERY: OPTIMIZATION, IN VITRO AND IN VIVO EVALUATION

UPENDRA C GALGATTE; PRAVIN D CHAUDHARI

doi:10.22159/ajpcr.2019.v12i4.31830

Authors

UPENDRA C GALGATTE Department of Pharmaceutics, Modern College of Pharmacy, Sector No. 21, Yamunanagar, Nigdi, Pune, India
PRAVIN D CHAUDHARI Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i4.31830

Keywords:

Drug targeting index, Frovatriptan, LCMS, Microemulsion, Nasal

Abstract

Objective: The main objective of the present research work was to develop, optimize, and characterize microemulsion (ME) of frovatriptan succinate to improve brain transport.

Methods: The pseudoternary phase diagrams were constructed for ME formulations composed of Capmul MCM, Cremophor EL, and propylene glycol. Frovatriptan succinate-loaded ME was optimized by simplex lattice design having the concentration of oil, surfactant, and cosurfactant representing three apex points on the triangle. These were taken as independent variables and percentage drug release as a response variable. All developed batches of ME were characterized for in vitro tests, histopathology study, and pharmacokinetics in Swiss albino rats.

Results: Clear MEs were obtained. F5 having particle size – 142.0 nm, zeta potential – 17.7–−7.8 mv, refractive index – 1.38±0.20, drug content – 98.24±0.20%, and drug diffused through dialysis membrane – 85% was the optimized batch. Drug permeation through the nasal mucosa of F5 in the ex vivo study was found to be 82.32%. Histopathology microscopic study has shown that F5 does not cause any irritation and structural changes in sheep nasal mucosa. The pharmacokinetic parameters were determined after nasal and oral administration of F5. For brain tissue, after nasal administration were Cmax181±1.51 ng/ml, Tmax – 2±1.01, area under curve (AUC)0−6 – 390.0±2.08 ng.h/ml. The AUC0−6 attained by nasal ME was 3.29 times greater than oral solution. Drug targeting index of frovatriptan succinate was 2.06. This was found satisfactory.

Conclusion: Microemulsion of said composition was found to be enhancing delivery of frovatriptan succinate to brain tissues through nasal route.

Downloads

Download data is not yet available.

References

Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002;7:967-75.

Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73.

Chen YW, Su KS, Chang SF. editors. Anatomy and physiology of the nose. In: Nasal Systemic Drug Delivery: Drugs and the Pharmaceutical Sciences. New York: Marcel Dekker Inc.; 1989. p. 1-19.

Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-8.

Talegaonkar S, Mishra PR. Intranasal delivery: An approach to bypass the blood brain barrier. Indian J Pharmacol 2004;36:140-7.

Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640-65.

Block LH. Pharmaceutical emulsions and microemulsions. In: Liberman HA, Rieger MM, editors. Pharmaceutical Dosage Forms: Disperse Systems. 2nded. New York: Informa Healthcare; 2008. p. 47 52.

Bölcskei H, Farkas B, Kocsis P, Tarnawa I. Recent advancements in anti-migraine drug research: Focus on attempts to decrease neuronal hyperexcitability. Recent Pat CNS Drug Discov 2009;4:14-36.

Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat 2008;4:49-54.

Balbisi EA. Frovatriptan: A review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag 2006;2:303-8.

Frovatriptan Monograph. Available from: http://www.drugs.com/ frovatriptansuccinate.html. [Last accessed on 2018 Jul 31].

Lianli L, Nandi I, Kim KH. Development of an ethyl laurate-based microemulsion forrapid-onset intranasal delivery of diazepam. Int J Pharm 2002;237:77-85.

Yadav SR, Gholse YN, Kawtikwar PS, Sakarkar DM. Design and evaluation of almond oil based water-in-oil mucoadhesive microemulsionfor nose to brain delivery. Int J Pharm Res 2011;3:48-52.

Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. Intranasal mucoadhesive microemulsions of clonazepam: Preliminary studies on brain targeting. J Pharm Sci 2006;95:570-80.

Vyas TK, Babbar AK, Sharma RK, Misra A. Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting. J Drug Target 2005;13:317-24.

Singh G, Rawat N, Singh K, Sarwal A, Sinha VR. Investigating the potential of an antidepressant intranasal mucoadhesive microemulsion. Int J Pharm Pharm Sci 2018;10:125-32.

Kawatikwar PS, Kulkarni NP, Yadav S, Sakarkar DM. Formulation and evaluation of an anti-epileptic drug loaded microemulsion for nose to brain delivery. Asian J Pharm 2009;3:143-7.

Pathak R, Dash RP, Misra M, Nivsarkar M. Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route. Acta Pharm Sin B 2014;4:151-60.

Zhu W, Yu A, Wang W, Dong R, Wu J, Zhai G, et al. Formulation design of microemulsion for dermal delivery of penciclovir. Int J Pharm 2008; 360:184-90.

Carter SJ, editor. Dispensing for Pharmaceutical Students. 12th ed. New York: CBS Publishers and Distributors Pvt., Ltd.; 2008. p. 120-2.

Dwivedi N, Kurmi BD, Kesharwani P, Shah J. Generation dependent targeting potential of donepezil loaded poly (propyleneimine) dendrimer through goat nasal mucosa. Int J Pharm Pharm Sci 2018;10:80-7.

Pote CW. Development Optimization and Evaluation of Microemulsion for Nasal Delivery [Dissertation]. Pune University; 2012.

Bhanushali RS, Gatne MM, Gaikwad RV, Bajaj AN, Morde MA. Nanoemulsion based intranasal delivery of antimigrain drugs for nose to brain targeting. Indian J Pharm Sci 2009;71:707-9.

Choi HG, Oh YK, Kim CK. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: Enhanced bioavailability. Int J Pharm 1998;165:23-32.

Laugher L, Briggs R, Doughty J, Noctor TA. Development of an analytical methodology from toxicokinetic to clinical studies for the anti-migraine drug frovatriptan. Chromatographia 2000;52:S113-9.

Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z, et al. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004;275:85-96.

Patel ZB, Patel KS, Shah AS, Surti NI. Preparation and optimization of microemulsion of rosuvastatin calcium. J Pharm Bioallied Sci 2012; 4:S118-9.

Bhattacharjee S. DLS and zeta potential – What they are and what they are not? J Control Release 2016;235:337-51.

Kumar A, Sharma P, Chaturvedi A, Jaiswal D, Bajpai M, Choudhary M, et al. Formulation development of sertraline hydrochloride microemulsion for intranasal delivery. Int J Chem Tech Res 2009;1: 941 7.

Piao HM, Balakrishnan P, Cho HJ, Kim H, Kim YS, Chung SJ, et al. Preparation and evaluation of fexofenadine microemulsion for intranasal delivery. Int J Pharm 2010;309-16.

Mandal S, Mandal SS, Naazneen S, Patel VB, Mandal PA. Design and development of saquinavir microemulsion for the oral bioavailability enhancement. Int J Pharm Tech Res 2009;4:1442-8.

Botner S, Sintov AC. Intranasal delivery of two benzodiazepines, midazolam and diazepam by a microemulsion system. Pharmacol Pharm 2011;2:180-8.

Lu W, Jiang W, Chen J, Yin M, Wang Z, Jiang X, et al. Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int J Pharm 2008;349:196-205.

Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358:285-91.

Jaiswal PL, Darekar AB, Saudagar RB. A recent review on nasal microemulsion for treatment of CNS disorder. Int J Curr Pharm Res 2017;9:5-13.